What is associated with increased side effects and lower perceived efficacy following switching to a generic medicine? A New Zealand cross-sectional patient survey.

ResearchSpace Repository

Show simple item record

dc.contributor.author MacKrill, Kate en
dc.contributor.author Petrie, Keith en
dc.date.accessioned 2019-03-18T23:15:35Z en
dc.date.issued 2018-10-18 en
dc.identifier.citation BMJ open 8(10):e023667 18 Oct 2018 en
dc.identifier.issn 2044-6055 en
dc.identifier.uri http://hdl.handle.net/2292/46089 en
dc.description.abstract OBJECTIVE:Following a switch from either a generic or branded antidepressant (venlafaxine) to a new generic, we investigated the factors associated with a preference for branded medicines, side effects reported following switching and efficacy ratings of the new generic drug. DESIGN:A cross-sectional survey of patients switched to a new generic. SETTING:Patients accessing venlafaxine information online from the New Zealand government pharmaceuticals funding website. PARTICIPANTS:310 patients, comprising 205 originally on branded venlafaxine and 105 previously taking a generic version. MAIN OUTCOME MEASURES:An online questionnaire assessing demographic factors, perceived sensitivity to medicines, trust in pharmaceutical agencies, sources of switch information, preference for branded medicine, new medicine perceptions, side effects and efficacy ratings. RESULTS:Preference for branded medicine was significantly stronger in older patients (OR=1.04, 95% CI 1.01 to 1.05), those taking branded venlafaxine (OR=2.02, 95% CI 1.13 to 3.64) and patients with a higher perceived sensitivity to medicine (OR=1.23, 95% CI 1.06 to 1.19). Different factors predicted side effects in those switching from the branded and those switching from the generic venlafaxine. Trust in pharmaceutical agencies and the number of side effects were significant predictors of efficacy ratings of the new generic in both patients switching from a branded and those switching from a generic version of venlafaxine. CONCLUSIONS:In patients switching from a branded medicine and those already taking a generic, different demographic and psychological factors are associated with preference for branded medicine, side effect reporting and perceived efficacy of the new drug. When switching to new generic, there appears to be a close bidirectional relationship between the experience of side effects and perceived drug efficacy. Trust in pharmaceutical agencies impacts directly on perceived efficacy and increasing such trust could reduce the nocebo response following a generic switch. en
dc.format.medium Electronic en
dc.language eng en
dc.relation.ispartofseries BMJ open en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.rights.uri https://creativecommons.org/licenses/by-nc/3.0/ en
dc.rights.uri https://creativecommons.org/licenses/by-nc/4.0/ en
dc.subject Humans en
dc.subject Antidepressive Agents en
dc.subject Drugs, Generic en
dc.subject Cross-Sectional Studies en
dc.subject Depressive Disorder en
dc.subject Age Factors en
dc.subject Adult en
dc.subject Aged en
dc.subject Middle Aged en
dc.subject Patient Satisfaction en
dc.subject Patient Acceptance of Health Care en
dc.subject New Zealand en
dc.subject Female en
dc.subject Male en
dc.subject Drug Substitution en
dc.subject Surveys and Questionnaires en
dc.title What is associated with increased side effects and lower perceived efficacy following switching to a generic medicine? A New Zealand cross-sectional patient survey. en
dc.type Journal Article en
dc.identifier.doi 10.1136/bmjopen-2018-023667 en
pubs.issue 10 en
pubs.begin-page e023667 en
pubs.volume 8 en
dc.rights.holder Copyright: The authors en
pubs.publication-status Published en
dc.rights.accessrights http://purl.org/eprint/accessRights/OpenAccess en
pubs.subtype Research Support, Non-U.S. Gov't en
pubs.subtype research-article en
pubs.subtype Journal Article en
pubs.elements-id 755591 en
pubs.org-id Medical and Health Sciences en
pubs.org-id School of Medicine en
pubs.org-id Psychological Medicine Dept en
dc.identifier.eissn 2044-6055 en
pubs.record-created-at-source-date 2018-10-21 en
pubs.dimensions-id 30341138 en

Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/3.0/ Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/3.0/
https://creativecommons.org/licenses/by-nc/4.0/ Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0/


Search ResearchSpace

Advanced Search